Plague in Biological Technology
Navigation Links
Plague in Biological Technology
... Restanza as a biodefense agent against anthrax, plague and tularemia.
On June 2, 2009, the FDA ... and reported from our ongoing pivotal studies in plague and tularemia by the end of 2009. We plan to ... against bioterror agents such as tularemia, plague and melioidosis. In June, the company announced ...
... of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com. Statement on Cautionary Factors Except for the ...
... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...
... "NCGA recognizes the potential value this research could provide our farmers in terms of new, safe approaches to control nematodes that plague corn and other crops," said Dr. Richard Glass, NCGA vice president of research and business development. "We are always seeking solutions ...
... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...
... Petri technology and will be the kit of choice whenever faster test results are essential." The bacteria responsible for Anthrax and Bubonic plague are category A select agents, due to their capacity to cause illness and death. These micro-organisms are a preferred bio-weapon of terrorists. As ...
... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for the ...
... mold remedy for mold removal and mold abatement exploiting the same technology that was used effectively on the toxic mold that spread like the plague in the wake of hurricane Katrina. Now professionals and homeowners alike can have a safe all natural alternative to chemical biocides or bleach for ...
... of DTRA funds are available over a nine-month base period to initiate NDA-enabling studies measuring cethromycin's efficacy in treating tularemia and plague as well as studies to measure cethromycin's efficacy in treating melioidosis. The remaining $2.0 million may be awarded over the ensuing 15 months ...
Tips from the journals of the American Society for Microbiology
... New Oral Vaccine May Protect Against Bubonic plague Researchers from the Institut Pasteur in ... ancestor to the highly infectious bubonic plague to develop a potentially safe, efficient and ... the world and can be treated; however, pneumonic plague is almost always fatal within 3 days of ....UCF professor develops vaccine to protect against black plague bioterror attack
... survived this challenge with no traces of the plague in their bodies. The rats were exposed to a heavy ... and then you convert them into capsules." The plague had a deadly impact on early Europe, it continues ... Organization reports at least 2,000 cases of the plague annually. The most recent outbreak in 2005 killed ...Tips from the journals of the American Society for Microbiology
... New Oral Vaccine May Protect Against Bubonic plague Researchers from the Institut Pasteur in ... ancestor to the highly infectious bubonic plague to develop a potentially safe, efficient and ... the world and can be treated; however, pneumonic plague is almost always fatal within 3 days of ....UCF professor develops vaccine to protect against black plague bioterror attack
... survived this challenge with no traces of the plague in their bodies. The rats were exposed to a heavy ... and then you convert them into capsules." The plague had a deadly impact on early Europe, it continues ... Organization reports at least 2,000 cases of the plague annually. The most recent outbreak in 2005 killed ...Tips from the journals of the American Society for Microbiology
... New Oral Vaccine May Protect Against Bubonic plague Researchers from the Institut Pasteur in ... ancestor to the highly infectious bubonic plague to develop a potentially safe, efficient and ... the world and can be treated; however, pneumonic plague is almost always fatal within 3 days of ....PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
... anthrax vaccine -- A recombinant dual antigen plague vaccine manufactured in E coli -- A third ... associated with its rPA anthrax vaccine and plague vaccine as well as certain government contracts ... its requirements for the rPA anthrax and plague vaccines. On March 28, 2008, Avecia received a ...PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
... (rPA) anthrax vaccine, a recombinant dual antigen plague vaccine, and a third generation rPA anthrax ... to Avecia's rPA anthrax vaccine programs and plague vaccine programs. Approximately 50 employees from ... contracts for the anthrax rPA vaccines and the plague vaccine, and royalties on sales to the ...Advanced Life Sciences Announces Second Quarter 2008 Financial Results
... of Defense DTRA contract to study cethromycin in tularemia, plague and melioidosis for up to $3.8 million; * Submitted funding ... A and B bioterror threats such as inhalation anthrax, tularemia, plague and melioidosis; * Published data in Journal of Antimicrobial ...PharmAthene Reports Second Quarter 2008 Financial and Operational Results
... vaccine, as well as RypVax(TM), the Company's recombinant dual antigen plague vaccine. Research and development expenses were $11.2 million and $4.0 ... nerve agents -- RypVax(TM) -- a recombinant dual antigen vaccine for plague -- a third generation rPA anthrax vaccine. For more information about ...PharmAthene Reports First Quarter 2008 Financial Results
... a chemical nerve agent bioscavenger, Protexia(R), and a novel dual antigen plague vaccine. Many of these programs are poised to achieve important milestones ... nerve agent poisoning; RypVax(TM), a recombinant dual antigen plague vaccine; and finally, third generation rPA anthrax vaccine technology. For ...PharmAthene Reports Year-End 2007 Financial Results
... recombinant Protective Antigen (rPA) anthrax vaccine, a novel dual antigen plague vaccine, RypVax(TM), and third generation anthrax vaccine technology. On ... of Defense (DoD) and that the DoD had decided not to fund Avecia's plague vaccine candidate beyond the current contractual commitments. The parties ...NASA technology helps predict and prevent future pandemic outbreaks
... Colorado, New Mexico, Arizona, and Utah, is a highly susceptible area for plague and Hanta virus outbreaks, and by understanding the mixture of vegetation, ... vectors within the region and the threat they cause to humans. Because plague is also considered a bioterrorism agent, NASA surveillance systems enable ...PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
... and treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) -- a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . ...... of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com. Statement on Cautionary Factors Except for the ...
Dow AgroSciences, NemGenix Establish New Collaboration in Plant Biotechnology
... capitalizes on the strengths of both Dow AgroSciences and NemGenix to develop next-generation technology to help combat parasitic nematodes, which plague millions of crop acres across the globe," said Daniel R. Kittle, Ph.D., vice president of R&D for Dow AgroSciences. "Dow AgroSciences is ...... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...
Assessment of safety and efficacy of human embryonic stem cell therapy
... discovery over a decade ago, hESCs have been considered a promising source of replacement cells for clinical studies. However, problems continue to plague clinical translation, including the risk of teratoma formation and the need for powerful drugs to overcome the problem of immune rejection. Until ...invivodata Announces ePROficiency 2009 Web Seminar Series
... 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, ...PharmAthene Reports First Quarter 2009 Financial and Operational Results
... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...... "NCGA recognizes the potential value this research could provide our farmers in terms of new, safe approaches to control nematodes that plague corn and other crops," said Dr. Richard Glass, NCGA vice president of research and business development. "We are always seeking solutions ...
... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...
NanoLogix Begins Construction of Production Facility for Medical Test Kits
... times faster than current Petri plate methods. Using the BNP(TM) they were able to view anthrax cultures in one-quarter of the time, and bubonic plague (Black Death) cultures in half of the time possible with the best traditional methods. The study appears in the current online issue of Letters in ...... Petri technology and will be the kit of choice whenever faster test results are essential." The bacteria responsible for Anthrax and Bubonic plague are category A select agents, due to their capacity to cause illness and death. These micro-organisms are a preferred bio-weapon of terrorists. As ...
PharmAthene Announces $5.5 Million Public Equity Offering
... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Contact: Stacey Jurchison ...SenesTech Scientists Attend International Workshop on Fertility in New Zealand
... the four year history of this annual meeting. SenesTech's initial product, ContraPest(TM), which is being developed to counteract the rice rat plague in the rice producing countries of the world, will dramatically improve rice yields in Southeast Asia by reducing the rice field rat population. Over ...invivodata and PRO Consulting to Present at International Industry Events
... 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, ...... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for the ...
Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results
... development of cethromycin as a potential broad-spectrum medical countermeasure against bioterror agents such as tularemia, plague and melioidosis; * Establishment of a strategic relationship with Inventiv Health to support pre-commercialization activities; ...ECBC's Environmental BioMonitoring Laboratory Focuses on the Future
... Sherlock Bioterrorism Library. In less than 10 minutes, the library can identify extract from anthrax, brucellosis, glanders, tularemia, melioidosis, plague and 15 challenge organisms. EBML serves as a leading technical resource and "go-to lab" that addresses environmentally-related ...Clemson researchers advance nanoscale electromechanical sensors
... between hydrogen and deuterium gas, very similar isotopes of the same element. Since the whole process is electrical, the size limitations that plague competing detection methods are not a problem here. The cantilevers can be shrunk down to the nano-scale and the operating electronics can be ...Pharmathene Reports Third Quarter 2008 Financial and Operational Results
... of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague -- a third generation rPA anthrax vaccine. For more information about PharmAthene, please visit http://www.PharmAthene.com . Statement on ...Clemson researchers advance nanoscale electromechanical sensors
... between hydrogen and deuterium gas, very similar isotopes of the same element. Since the whole process is electrical, the size limitations that plague competing detection methods are not a problem here. The cantilevers can be shrunk down to the nano-scale and the operating electronics can be ...... mold remedy for mold removal and mold abatement exploiting the same technology that was used effectively on the toxic mold that spread like the plague in the wake of hurricane Katrina. Now professionals and homeowners alike can have a safe all natural alternative to chemical biocides or bleach for ...
US College Students Needing TB Testing Now Have the Benefit of QFT(TM)
... to cross-reactivity with BCG vaccine and commonly encountered environmental non-tuberculous mycobacteria. False-positive TST responses particularly plague students from high TB incidence countries as many of them are vaccinated with BCG at birth. Reading a TST response is subjective and large ...... of DTRA funds are available over a nine-month base period to initiate NDA-enabling studies measuring cethromycin's efficacy in treating tularemia and plague as well as studies to measure cethromycin's efficacy in treating melioidosis. The remaining $2.0 million may be awarded over the ensuing 15 months ...
Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
... and treatment of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) -- a recombinant dual antigen vaccine for plague a third generation rPA anthrax vaccine. For more information about PharmAthene, please visit http://www.PharmAthene.com . Statement on ...Nanowires may boost solar cell efficiency, UC San Diego engineers say
... in February 2008. If you provide electrons with a defined pathway to the electrode, you can reduce some of the inefficiencies that currently plague thin-film solar cells made from polymer mixtures. More efficient transport of electrons and holes collectively known as carriers is critical for ...Advanced Life Sciences Announces First Quarter 2008 Financial Results
... of Health and Human Services to fund the advanced development of cethromycin in combating bioterror agents such as anthrax, tularemia, plague and Burkholderia pseudomallei; * Initiate enrollment by the end of the summer in Phase I/II dose-escalating study to assess the safety, ...Other ContentsbrokenbrokenbrokenbrokenbrokenbrokennailsnailsbrittlebrittlebrittlebroadbroadbroadbroadbroadbroadbroadbroadbroadbroadbronchiectasisbronchitisbronchitisbronchitisbronchoscopybronchoscopybronchiolitisbronchiolitisOther TagsINFORMINFORMINFORMINFORMINFORMINFORM
(Date:12/16/2009)... iQor, a global provider of business process ... InfoWorld 100 Awards Top 100 IT project of ... the first submission for iQor. ,, "We are honored ... said Vikas Kapoor, president and CEO of iQor. "TeQ21 ... us to work faster, smarter and with the added ...
(Date:12/16/2009)... HARBOR, Fla., Dec. 2 Communication ... a leading supplier of electronic signature solutions ... industry* and the recognized leader** in biometric ... a leading International Electronic Document Management (EDM) ... entered an agreement to provide their products ...
(Date:12/16/2009)... Texas, Dec. 8, 2009 National ... in industrial measurement and control, and DENSO ... automation using robotics technology, today announced their ... technology with DENSO robotic arms. The collaboration ... research and flexible manufacturing applications. In today,s ...
Breaking Biology News(10 mins):iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5Garner to Lead Virginia Bioinformatics Institute 14513 1Garner to Lead Virginia Bioinformatics Institute 14513 2Garner to Lead Virginia Bioinformatics Institute 14513 3MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference 26amp 3B Exhibition 5539 1MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference 26amp 3B Exhibition 5539 2MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference 26amp 3B Exhibition 5539 3MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference 26amp 3B Exhibition 5539 4ESC press statement 3A Cigarettes on sale on the internet 59661 1ESC press statement 3A Cigarettes on sale on the internet 59661 2ESC press statement 3A Cigarettes on sale on the internet 59661 3(Date:12/16/2009)... Inc. (Nasdaq: BLUD ), a global leader in ... today announced that Paul D. Mintz, M.D. has been ... effective January 1, 2010. ,, Dr. Mintz has ... more than 30 years. He is a tenured Professor ... School of Medicine. He also serves as director of ...
(Date:12/16/2009)... -- Allscripts (Nasdaq: MDRX ) announced today ... the three and six months ended November 30, ... January 11, 2010. Allscripts management will host a ... earnings and other information at 8:30 AM Eastern ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second quarter ...
(Date:12/16/2009)... The most widely used human embryonic stem cell ... justice questions that must be addressed to ensure that ... according to a University of Michigan research team. ,, ... U-M team analyzed 47 embryonic stem cell lines, including ... researchers. The scientists determined the genetic ancestry of each ...
(Date:12/16/2009)... Institute will sponsor a new learning collaborative ... who serve individuals at risk of, or ... plan, medical home and other provider settings. ... webinars on topics, solutions and case studies ... improvement. Each webinar will include a brief ...
(Date:12/16/2009)... Scientists pinpoint seven that increase susceptibility to disease ... genes associated with increased susceptibility to leprosy have ... , The researchers, who analyzed more than 10,000 ... in China, said their discovery highlights the important ... the development of leprosy. , "Though leprosy is ...
Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Leprosy Genes Identified 2[1] Immucor Appoints New Board Director[0] Allscripts to Announce Second Quarter Fiscal 2010 Results[0] U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines[1] New Learning Collaborative to Prepare Clinicians for Better Chronic Care[0] Leprosy Genes Identified
KLEPPINGERINFORMAfinionFungitellCanDia5SYSCAN3AlbiQuickOsiriseClinicalWorksUroChartmeridianEMRMedcomSoftPolymedCellaVision
Other Tagsinterpreted 2interpreted 3therapy 2therapy 3therapy 4therapy 5therapy 6therapy 7therapy 8therapy 9therapy 10radiation 2radiation 3radiation 4radiation 5radiation 6radiation 7radiation 8radiation 9adding 2adding 3adding 4adding 5adding 6adding 7adding 8adding 9adding 10structures 2structures 3structures 4structures 5structures 6structures 7structures 8structures 9structures 10genome 2genome 3genome 4genome 5genome 6genome 7genome 8genome 9genome 10share 2share 3share 4share 5share 6share 7share 8share 9share 10| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |